Skip to main content
SpringerLink
Log in
Book cover

Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s pp 231–240Cite as

Therapeutic Possibilities with Serotonergic Drugs

  • Chapter

  • 109 Accesses

Summary

The majority of serotonergic drugs act either via blocking uptake of serotonin (5-hydroxytryptamine; 5-HT) into serotonergic neurons or by an action on a growing number of serotonin receptors. Based on operational (agonist and antagonist rank order), transductional (second messenger coupling) and structural (gene and amino acid sequence) criteria, four main types of serotonin receptors have been discerned. The responses mediated via many serotonin receptors are now well understood and this, in turn, has resulted in the development and use of serotonergic drugs in the therapy of several diseases, including anxiety and migraine, and in the prevention of vomiting caused by anticancer agents. Many other therapeutic avenues are being explored.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986; 25: 563–576.

    Article  PubMed  CAS  Google Scholar 

  2. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA. International union of Pharmacology Classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994; 46: 157–203.

    PubMed  CAS  Google Scholar 

  3. Gerald C, Adham N, Kao HT, Schechter IE, Olsen MA, Bard JA, et al. The 5-HT4 receptor: molecular cloning of two splice variants. In: Abstracts Book, Third IUPHAR Satellite Symposium on Serotonin, Chicago, 1990: 82.

    Google Scholar 

  4. Saxena PR. Modern 5-HT receptor classification and 5-HT based drugs. Exp. Opin. Inv. Drugs 1994; 5: 513–523.

    Article  Google Scholar 

  5. Charney DS, Krystal JH, Delgado PL, Heninger GR. Serotonin-specific drugs for anxiety and depressive disorders. Ann. Rev. Med. 1990; 41: 437–446.

    Article  PubMed  CAS  Google Scholar 

  6. Murphy DL, Broocks A, Aulakh C, Pigott TA. Anxiolytic effects of drugs acting on 5-HT receptor subtypes. In: Vanhoutte PM, Saxena PR, Paoletti R, Brunello N, Jackson AS, editors. Serotonin, cell biology to pharmacology and therapeutics. Dordrecht: Kluwer Academic Publishers, 1993: 223–230.

    Google Scholar 

  7. Kilpatrick GJ, Ireland SJ, Tyers MB. Ondansetron and related 5-HT3 antagonists: recent advances. Prog. Med. Chem. 1992; 29: 239–270.

    Article  PubMed  Google Scholar 

  8. Barnes JM, Costali B, Coughlan J, Domeney AM, Gerrard PA, Kelly ME, et al. The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharmacol. Biochem. Behav. 1990; 35: 955–962.

    Article  PubMed  CAS  Google Scholar 

  9. Chugh Y, Saha N, Sankaranarayanan A, Datta H. Enhancement of memory retrieval and attenuation of scopolamine-induced amnesia following administration of 5-HT3 antagonist ICS 205–930. Pharmacol. Toxicol. 1991; 69: 115–116.

    Article  Google Scholar 

  10. Pitikas N, Brambilla A, Borsini F. Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task. Pharmacol. Biochem. Behav. 1994; 47: 95–99.

    Article  Google Scholar 

  11. Domeney AM, Costali B, Gerrard PA, Jones DN, Naylor RJ, Tyers MB. The effect of ondansetron on cognitive performance in the marmoset. Pharmacol. Biochem. Behav. 1991; 38: 169–175.

    Article  PubMed  CAS  Google Scholar 

  12. Hagan RM, Kilpatrick GJ, Tyers MB. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology 1993; 112: S68–S75.

    Article  PubMed  CAS  Google Scholar 

  13. DeVeaugh-Geiss J, McBain S, Cooksey P, Bell JM. The effects of a novel 5-HT3 antagonist, ondansetron, in schi-ophrenia: results from uncontrolled trials. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press, 1992: 225–232.

    Google Scholar 

  14. McBain SL, Dineen M, Weiler M, Taylor S, Cooksey P, Williams P, et al. Ondansetron: a double-blind placebo-controlled study in acute schizophrenia. Schizophren. Res. 1992; 6: 112.

    Article  Google Scholar 

  15. Newcomer JW, Faustman WO, Zipursky RB, Csernansky JG. Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial. Arch. Gen. Psychiat. 1992; 49: 751–752.

    Article  PubMed  CAS  Google Scholar 

  16. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol. Sci. 1993; 14: 129–1233.

    Article  PubMed  CAS  Google Scholar 

  17. Hyer D, Schoeffter P. Interactions of dihydroergotamine (DHE), ergotamine and GR 43175 (sumatriptan) with 5-HT1D receptors. Naunyn-Schmiedebergs Arch. Pharmacol. 1991; 343: R111.

    Google Scholar 

  18. Bruinvels AT, Lery H, Nozulak J, Palacios JM, Hoyer D. 5-HTID binding sites in various species: similar pharmacological profile in dog, monkey, calf, guinea-pig and human brain membranes. Naunyn-Schmiedebergs Arch. Pharmacol. 1992; 346: 243–248.

    PubMed  CAS  Google Scholar 

  19. Müller-Schweinitzer E. Ergot alkaloids in migraine: is the effect via 5-HT receptors? In: Olesen J, Saxena PR, editors. 5-Hydroxytryptamine mechanisms in primary headache. New York: Raven Press, 1992: 297–304.

    Google Scholar 

  20. Ferrari MD. 5-HT3 receptor antagonists and migraine therapy. J. Neurol. 1991; 238(Suppl. 1): S53–S56.

    Article  PubMed  Google Scholar 

  21. Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer drugs. Trends Pharmacol. Sci. 1988; 9: 334–341.

    Article  PubMed  CAS  Google Scholar 

  22. Hesketh PJ, Gandara DR. Serotonin Antagonists: A new class of antiemetic agents. J. Natl. Cancer Inst. 1991; 83: 613–620.

    Article  PubMed  CAS  Google Scholar 

  23. Kois MG, Baltzer L, Pisters KRN, Tyson LB. Enhancing the effectiveness of the specific serotonin antagonists. Combination with dexamethasone. Cancer 1993; 72: 3436–3442.

    Article  Google Scholar 

  24. Fumagalli I, Hamner B. Cisapride versus metaclopramide in the treatment of functional dyspepsia. A double-blind comparative trial. Scand. J. Gastroenterol. 1994; 29: 33–37.

    Article  PubMed  CAS  Google Scholar 

  25. Corinaldesi R, Stanghellini V, Tosetti C, Rea E, Corbelli C, Marengo M, et al. The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur. J. Clin. Pharmacol. 1993; 44: 429–432.

    Article  PubMed  CAS  Google Scholar 

  26. Mackie ADR, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment. Pharmacol. Ther. 1991; 5: 135–142.

    Article  PubMed  CAS  Google Scholar 

  27. Arantikakis G, Nikopoulos A, Theohardis A, Giannoulis E, Vagios I, Anthopoulou H, et al. Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease — A comparative randomized double-blind trial. Aliment. Pharmacol. Ther. 1993; 7: 635–641.

    Google Scholar 

  28. Ford APDW, Clarke DE. The 5-HT4 receptor. Med. Res. Revs. 1993; 13: 633–662.

    Article  CAS  Google Scholar 

  29. Mayer EA, Gebhart GF. Functional bowel disorders and the visceral hyperalgesia hypothesis. In: Mayer EA, Raybould HE, editors. Basic and clinical aspects of chronic abdominal pain. New York: Elsevier Science Publishers, 1993: 3–28.

    Google Scholar 

  30. Steadman CJ, Talley JJ, Phillips SF, Zinsmeister AR. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhoea-predominant irritable bowel syndrome: A pilot study. Mayo Clinic Proc. 1992; 67: 732–738.

    CAS  Google Scholar 

  31. Banner SE, Smith MI, Sanger GJ. 5-HT Receptors and 5-hydroxytryptophan-evoked defecation in mice. Br. J. Pharmacol. 1993; 111: 135P.

    Google Scholar 

  32. Hegde SS, Moy TM, Perry MR, Eglen RM. Involvement of 5-HT4 receptors in 5-hydroxytryptophan-induced diarrhoea in mice. FASEB 1994; 8: A92.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Faculty of Medicine and Health Sciences, Erasmus University Rotterdam, Post Box 1738, 3000, DR Rotterdam, The Netherlands

    Pramod R. Saxena

  2. Institute of Pharmacology, Syntex Research, Palo Alto, CA, 94303, USA

    David E. Clarke & Anthony P. D. W. Ford

  3. Preclinical Research Division, Sandoz Pharma Ltd., CH 4002, Basel, Switzerland

    Daniel Hoyer

  4. Department of Pharmacology, University of Sydney, Sydney, NSW, Australia

    Ewan J. Mylecharane

  5. Research Division, Glaxo Research and Development Ltd., Ware, UK

    Michael B. Tyers & Jullie C. Barnes

  6. CNS Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492, USA

    Frank D. Yocca

Authors
  1. Pramod R. Saxena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David E. Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony P. D. W. Ford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Hoyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ewan J. Mylecharane
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael B. Tyers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jullie C. Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Frank D. Yocca
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology and Therapeutics Mclntyre Medical Sciences Building, McGill University, 3655 Drummond Street, Montreal, Quebec, Canada, H3G 1Y6

    A. Claudio Cuello  & Brian Collier  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Saxena, P.R. et al. (1995). Therapeutic Possibilities with Serotonergic Drugs. In: Cuello, A.C., Collier, B. (eds) Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s. Birkhäuser Basel. https://doi.org/10.1007/978-3-0348-7218-8_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7218-8_23

  • Publisher Name: Birkhäuser Basel

  • Print ISBN: 978-3-0348-7220-1

  • Online ISBN: 978-3-0348-7218-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation